SCA
GBT

Secor Capital Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Secor Capital Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-45,870
Closed -$1.8M – 674
2017
Q4 		$1.8M Sell
45,870
-16,242
-26% -$607K 0.07% 215
2017
Q3 		$1.93M Sell
62,112
-2,680
-4% -$75.4K 0.18% 174
2017
Q2 		$1.77M Buy
+64,792
New +$1.93M 0.16% 196

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Secor Capital Advisors's GBT Position: Q1 2018 in Review

Secor Capital Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2018, closing a stake of 45,870 shares — an estimated $1.8M sold.

Secor Capital Advisors first reported a position in GBT in Q2 2017 and held it in 3 quarters. The position peaked at $1.93M in Q3 2017. 176 funds tracked by Wall St. Rank hold GBT as of Q1 2018.

  • Secor Capital Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 45,870 Global Blood Therapeutics, Inc. shares in Q1 2018, an estimated $1.8M.
  • Secor Capital Advisors first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Secor Capital Advisors's Global Blood Therapeutics, Inc. position peaked at $1.93M in Q3 2017.
  • 176 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2018.

Based on Secor Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.